NCIt definition : A recombinant human-derived monoclonal antibody targeting the tumor cell-protective
protein complement factor H (CFH), with potential immunomodulatory and antineoplastic
activities. Upon administration, the anti-CFH monoclonal antibody GT103 targets and
binds specifically to a conformationally distinct epitope within a specific crucial
functional domain of CFH bound on tumor cells. This activates the complement cascade,
triggers complement dependent cytotoxicity and leads to the destruction of the tumor
cells. In addition, GT103 modulates the adaptive anti-tumor immune response, thereby
reducing the number of immune suppressive T regulatory cells (Tregs) and myeloid-derived
suppressor cells (MDSCs) in the tumor. This may potentially provide long-term anti-tumor
immunity and protection. CFH, the major regulator of the central complement protein
C3b in the alternative pathway of complement activation, normally prevents cells from
destruction by the immune system. CFH may play a key role in protection against complement-mediated
lysis in various cancer cells.;
Semantic type(s)